Early trial tests new drug duo for rare Muscle-Wasting disease
NCT ID NCT06479863
Summary
This is a small, early-stage pilot study testing whether a combination of two drugs, pozelimab and cemdisiran, can help control the progression of sporadic inclusion body myositis (sIBM), a rare muscle-wasting disease. Ten participants will receive injections every four weeks for two years, with the goal of measuring changes in muscle strength, walking ability, and daily function. The study will closely monitor safety and how well participants can perform key physical tasks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC INFLAMMATORY MYOPATHIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Austin Neuromuscular Center
RECRUITINGAustin, Texas, 78759, United States
-
Austin Neuromuscular Center
RECRUITINGAustin, Texas, 78759, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.